ClinicalTrials.gg
Not yet recruitingNCT07694466Updated Nov 4, 2026

Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis

An Early Phase 1 interventional study of Cannabis (THC) and Tobacco Cigarette in Cannabis Use, Tobacco and Biomarkers, sponsored by Hannah Harris. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Hannah Harris · Early Phase 1, Interventional, and Basic science

Updated Nov 4, 2026Start date movedGo to Updates ↓
Phase
Early Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This outpatient study examines how inhaled cannabis, combustible or vaporized, alters lung health and breath biomarkers compared to a tobacco cigarette.

02

Conditions studied

  • Cannabis Use
  • Tobacco
  • Biomarkers

Browse trials for

Keywords

  • vaping
  • cannabis
  • tobacco
03

In context

Vaping

402 studies on the registry are indexed under Vaping; 95 are open to participants now.

This study's planned enrollment of 12 is below the median of 79 across 322 interventional studies indexed under Vaping.

Browse Vaping studies →

Lead sponsor

Hannah Harris is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. English-speaking,
  2. Literate adults,
  3. Male or female,
  4. Between the ages of 18 and 55,
  5. from 18.5 and 32.0 kg/m2,
  6. Able to provide written and perform all study procedures,
  7. Current recreational cannabis users - must report past 30-day cannabis use and at least 5 exposures in the past year (minimum use criteria); no limit on maximum use,
  8. Past year history of vaporized or smoked cannabis use to intoxication,
  9. Past 30-day use of combusted tobacco,
  10. Not currently seeking treatment for cannabis, tobacco cigarettes, or other drug use,
  11. If female, a negative pregnancy test and use of an effective form of during study participation (e.g., oral contraceptive, abstinence, barrier method),
  12. Negative urine drug test for drugs of abuse (other than cannabis) before every Laboratory Session, and
  13. Otherwise, healthy as determined by the investigator based on medical history, physical examination, vital signs, laboratory chemistries (blood chemistry with liver function tests and hematology, urinalysis, and microscopic evaluation, 12-lead ).

Exclusion criteria

Exclusion Criteria:

  1. Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and/or alcohol that would require medical management,
  2. acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders [e.g., asthma, ]),
  3. Existing or significant lung health problems that could interfere with the study,
  4. Current or history of major psychiatric disorder that would limit the participant's ability to participate in the study (e.g., bipolar disorder),
  5. Exclusive use of tobacco or cannabis through vapes and Electronic Nicotine Delivery Systems (ENDS) products,
  6. Currently using daily prescription medications to manage medical conditions or any drug that could interfere with the study (as determined by the study physician),
  7. Clinically significant abnormal (as determined by study physician/cardiologist),
  8. Clinically significant abnormal laboratory findings (e.g., liver function tests greater than 3x the ),
  9. History of seizure disorder,
  10. Clinically significant history of head injuries requiring medical management or long-lasting sequelae.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Active comparator
    Tobacco Cigarette

    Participants will inhale a leading brand of tobacco cigarette (\~1.0 gram; Marlboro Gold; Phillip Morris International).

    Drug: Tobacco Cigarette

  • Experimental
    Vaporized Cannabis (THC)

    Participants will receive a non-therapeutic, active vaporized marijuana.

    Drug: Cannabis (THC)

  • Experimental
    Combustible Cannabis (THC)

    Participants will receive a non-therapeutic, active smoked marijuana.

    Drug: Cannabis (THC)

Interventions

  • Active Cannabis (THC) will be inhaled.

  • DrugTobacco Cigarette

    A leading brand of tobacco cigarette (\~1.0 gram; Marlboro Gold; Phillip Morris International)

06

What researchers measure

Primary outcomes

  1. Exhaled Breath Condensate (EBC)

    To capture Exhaled Breath Condensate (EBC) samples, the participant will inhale and exhale normally through an RTube device for \~10 minutes. The RTube will separate saliva from the main exhaled stream in the blue "Tee" section of the mouthpiece. The exhaled stream passes through a one-way duckbill valve into a gray condensation tube. Samples can be analyzed using Inductively Coupled Plasma Mass Spectrometry (ICP-MS). The primary outcome of this measure is the identification of metals, proteins, as well as non-volatiles present before and after drug administration conditions.

    Time frame: Baseline (prior to study drug admission), approximately 25, 40,60, 90, 120 and 180 minutes after drug administration

  2. Breath Volatile Organic Compound (BVOC)

    For this test, participants will place the ReCIVA Breath Sampler device over their nose and mouth for \~15 minutes and breathe normally. Exhaled breath volatile organic compounds (BVOC) are collected on Breath Biopsy Cartridges and can be analyzed using Thermal Desorption-Gas Chromatography-Mass Spectrometry (TD-GC-MS) to identify over 200 volatile organic compound (VOC) biomarkers. The primary outcome of this measure is the identification of BVOC biomarkers present before and after drug administration conditions.

    Time frame: Baseline (prior to study drug admission), approximately 25, 40,60, 90, 120 and 180 minutes after drug administration

  3. Exhaled Nitric Oxide (FeNO)

    Elevated FeNO levels serve as a biomarker for airway inflammation. To measure this, the NIOX VERO FeNO device will be used. Participants will insert the NIOX mouthpiece into their mouth and be instructed to inhale through the device and, when prompted, exhale for \~10 seconds. The primary outcome of this measure is the level of FeNO present before and after drug administration conditions.

    Time frame: Baseline (prior to study drug admission), approximately 25, 40,60, 90, 120 and 180 minutes after drug administration

Secondary outcomes

  1. Cigarette Evaluation Questionnaire (CEQ)

    Immediately following drug administration of tobacco or cannabis cigarettes, participants are to rate each cigarette on a scale from 0 'Not at all' to 7- 'Extremely' for questions on satisfaction, similarity to usual brand, psychological reward, aversion, enjoyment of respiratory sensations, and perceived strength.

    Time frame: Immediately following administration of combusted tobacco or cannabis cigarette (approximately 10 minutes after drug administration)

  2. Modified Cigarette Evaluation Questionnaire (mCEQ)

    Immediately following drug administration of vaped cannabis, each participant will rate vaped cannabis on a 7-point response scale of 0 - 'Not at all' to 7- 'Extremely' for questions on satisfaction, similarity to usual brand, psychological reward, aversion, and enjoyment of respiratory sensations.

    Time frame: Immediately following administration of vaporized cannabis (approximately 10 minutes after drug administration)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Feb 2027, 2 months later.

Start moved twice since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, last on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jul 10, 2026
StartEst.
Dec 1, 2026was Oct 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Dec 1, 2026
moved 2 times, Oct 6, 2026 – Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    Start date Nov 1, 2026→Dec 1, 2026
    + 1 other change: verification date
  2. Oct 6, 2026
    Start date Oct 1, 2026→Nov 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07694466
Lead sponsor
Hannah Harris
Responsible party
Hannah Harris (Assistant Professor, University of Kentucky) — Sponsor-investigator
First posted
Jul 10, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Paul A Nuzzo, M.A.
Contact
pnuzz2@email.uky.edu
859-323-0002
Hannah M Harris, Ph.D.
principal investigator · University of Kentucky

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabis sativa subsp. indica TOP

Start the discussion